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A more effective gene therapy strategy for lung cancer using sequential 
cisplatin administration and adenovirus-mediated p53 gene transfer was 
developed on the basis of our previous observation of enhanced expression 
of a reporter gene in malignant cells exposed to cisplatin before gene 
transfer. Transfer of the normal (wildtype) p53 gene into cisplatin-treated 
H1299 cells, in which p53 is homozygously deleted, resulted in up to a 60% 
further inhibition of cell proliferation in vitro than p53 transfer into 
untreated H1299 cells. The cisplatin plus p53 gene transfer strategy yielded 
significantly greater apoptosis and tumor growth suppression in an animal 
model of subcutaneous H1299 tumor nodules than wildtype p53 gene 
transfer alone. The timing of cisplatin administration and p53 gene 
transfer was shown to be critical: cisplatin administration simultaneous 
with or subsequent o p53 gene transfer was less effective than cisplatin- 
first sequential treatment. Moreover, the in vivo inhibition of tumor growth 
was maintained by repeated cycles of treatment. This gene therapy strategy 
has been incorporated into a phase I clinical trial for the treatment of lung 
cancer and provides a basis for the development of improved therapeutic 
protocols. (J Thorac Cardiovasc Surg 1996;112:1372-7) 
M utations of the p53 tumor suppressor gene have been found in up to 60% of non-small-cel l  lung 
carcinomas (NSCLC).  1 Restorat ion of normal  p53 
function in cells with p53 mutat ions by gene replace- 
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ment leads to G1 cell cycle arrest or induction of 
apoptosis. 2 A recombinant  adenovirus expressing 
the p53 gene (Adv-p53) has been shown to mediate 
tumor growth inhibit ion both in vitro and in vivo. 3' 4 
However,  in some cases mal ignant cells may even- 
tually resume growth, some at the same rate as 
untreated cells, after complet ion of gene transfer. 3'4 
We 5 previously demonstrated that a br ief  exposure 
of NSCLC cells to the chemotherapeut ic  agent 
cisplatin (c isdiamminodichloroplat inum; CDDP)  
before adenovirus-mediated gene transfer enhanced 
target cell expression of a reporter  gene in vitro and 
in vivo. In this study, we exploited this salutary effect 
of CDDP on gene expression by designing a novel 
gene therapy strategy for lung cancer that comprises 
sequential  CDDP administrat ion and adenovirus- 
mediated p53 gene transfer. We hypothesized that 
the resulting increased p53 gene expression in target 
cells may lead to an enhanced tumoric idal  effect. 
Materials and methods 
Cell proliferation assay. H1299 cells (human NSCLC 
cells with a homozygous deletion of p53) were exposed to 
CDDP at a concentration of0.062/xg/ml of medium for 24 
hours. Forty-eight hours later, cells were infected with 
Adv-p53 at a multiplicity of infection (MOI: number of 
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viral particles per cell) of 1 or 5. Daily cell counts were 
performed for 5 days after infection. Controls consisted of 
untreated cells, cells exposed to CDDP only, cells infected 
with Adv-p53 only, and cells infected with d1312 (EIA- 
deleted adenovirus used as control vector) with or without 
prior CDDP treatment. 
In situ TUNEL assay for apoptosis. Terminal deoxynu- 
cleotidyl transferase-mediated dUTP-biotin nick end- 
labeling (TUNEL) assay was performed on CDDP- 
treated or control H1299 cells 12 hours and 24 hours after 
infection with Adv-p53 and on cells of the control groups 
(as described earlier) at the same time points (MOI = 5). 6 
The fractions of TUNEL-positive cells were determined 
by flow cytometry (EPICS Profile II, Coulter Corp., 
Hialeah, Fla.). In situ TUNEL assay was also performed 
on frozen tissue sections of tumor nodules harvested 24 
hours after intratumoral injections with Adv-p53 or 
d1312. 6Positive controls were normal cells or tissue sec- 
tions treated with DNAse I (Gibco-BRL, Gaithersburg, 
Md.). 
In vivo combination of sequential CDDP and Adv-p53. 
H1299 tumor xenografts were established in the subcuta- 
neous spaces of nu/nu mice. An intraperitoneal CDDP 
injection (5 /~g/gm body weight) was given on day 0 
followed by an intratumoral injection of 5 × 109 Adv-p53 
particles in 100 /~1 of phosphate-buffered saline solution 
(PBS) on days 2, 4, and 6. Other CDDP and Adv-p53 
combinations were also studied for their tumoricidal 
efficacy: simultaneous intraperitoneal CDDP and Adv- 
p53 administration in three equally divided doses (CDDP: 
1.67/zg/gm body weight) on days 2, 4, and 6 or intraper- 
itoneal CDDP (5 /zg/gm body weight) given on day 8 (2 
days after completion of three intratumoral Adv-p53 
injections on days 2, 4, and 6). In two other groups of 
mice, a second cycle of gene therapy was given 10 days 
after completion of the first cycle to study the therapeutic 
efficacy of repeated therapy. Tumor sizes were measured 
every 2 days for 32 days, and tumor volumes were 
estimated by assuming a spherical shape with the average 
tumor diameter calculated as the square root of the 
product of the orthogonal diameters; n = 5 per group. 
All animals received humane care in compliance with 
the "Principles of Laboratory Animal Care" formulated 
by the National Society for Medical Research and the 
"Guide for the Care and Use of Laboratory Animals" 
prepared by the Institute of Laboratory Animal Resources 
and published by the National Institutes of Health. 
Results and discussion 
Treatment with either CDDP or infection with 
dl312 with or without prior CDDP exposure had no 
effect on H1299 cell growth in vitro. However, 
H1299 cells exposed to a low concentration of 
CDDP (0.062 /xg/ml) 48 hours before Adv-p53 
infection had a 31% to 60% greater inhibition of cell 
proliferation than cells infected only with Adv-p53. 
This inhibition was apparent as early as 3 days after 
gene transfer at MOI  of 1 and 5, respectively (Fig. 
1). This combination strategy also resulted in a 
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Fig. 1. Enhancement of the tumor killing effect by the 
combination of CDDP and Adv-p53 in vitro (*p < 0.01 vs 
PBS/Adv-p53 by Student's t test). Cells counts performed 
on day 3 after Adv-p53 infection are shown here (n = 5). 
higher level of p53 protein expression at 12, 24, 36, 
and 48 hours after virus infection than in cells 
infected with Adv-p53 alone as determined by a 
quantitative Western blot analysis as described else- 
where. 7 Densitometry analysis showed that the rel- 
ative levels of p53 protein in CDDP-treated cells 
(normalized for /3-actin levels) were twofold to 
threefold higher than in Adv-p53-infected cells 
without prior CDDP exposure (data not shown). 
Although fewer than 5% of cells in other control 
groups stained positive for apoptosis by TUNEL  
assay, 19.2% and 68.5% of cells infected with Adv- 
p53 only (MOI = 5) were TUNEL-positive at 12 
hours and 24 hours after p53 gene transfer. The 
fractions of apoptotic ells were significantly higher 
(50.2% and 90.8% at the same time points) in cells 
treated by the combination of CDDP and Adv-p53. 
The higher levels of p53 gene expression achieved 
by this combination gene transfer strategy may 
enhance induction of apoptosis, which would trans- 
late to increased inhibition of tumorigenicity. 
In the in vivo studies, intraperitoneal dministra- 
tion of CDDP resulted in only a slightly greater 
reduction in tumor growth (Fig. 2, A). Tumors 
injected with d1312, with or without prior intraperi- 
toneal CDDP, showed some degree of growth retar- 
dation. Intratumoral injections of Adv-p53 without 
CDDP inhibited tumor growth during and immedi- 
ately after the treatment (Fig. 2, A), but these 
tumors resumed growth and attained a mean tumor 
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Fig. 2. Enhanced in vivo inhibition of tumorigenesis by sequential intraperitoneal CDDP and 
intratumoral Adv-p53 injections. A, Analysis of timing of CDDP administration with intraperitoneal 
CDDP given either before, concurrent (CDDP+Adv-p53) with, or after (Adv-p53/CDDP) intratu- 
moral injections of Adv-p53 (**p < 0.01 CDDP/Adv-p53 vs other groups by analysis of variance and 
Student's t test). B, Analysis of the effect of a second course of gene therapy. The symbols # and * denote 
PBS and CDDP groups, respectively (#,*p < 0.01 vs one cycle of therapy by Student's t test). For both 
experiments, the controls were tumor-bearing animals injected with PBS (PBS), Adv-p53 without prior 
intraperitoneal CDDP (PBS/Adv-p53), or d1312 with or without prior intraperitoneal CDDP (CDDP/dl312 
or PBS/dl312). 
volume of 3357 _+ 391 mm 3 32 days after the onset 
of therapy. However, the combination of intraperi- 
toneal CDDP gene therapy resulted in a pro- 
nounced inhibition of tumor development: at the 
end of the observation period, the average tumor 
size was 1497 _+ 221 mm 3 (p < 0.01 vs Adv-p53 
without prior CDDP). Systemic CDDP administra- 
tion before p53 gene replacement therapy, there- 
fore, produced a synergistic tumor growth inhibition 
effect that was responsible for at least a 55.4% 
further reduction in tumor size. Moreover, the 
timing of intraperitoneal CDDP administration was 
of critical importance, inasmuch as the sequential 
combination of CDDP and Adv-p53 showed a more 
significant umor growth inhibitory effect than the 
other two dosing schedules (Fig. 2, A). A second 
cycle of gene therapy further inhibited tumorigene- 
sis. Of the groups that received a second cycle, the 
CDDP-treated group had a significantly higher de- 
gree of tumor growth suppression (54.6%) than the 
PBS-treated group (35.7%), and both groups had 
significantly higher degrees of tumor growth sup- 
pression than the respective groups receiving a 
single cycle of therapy (Fig. 2, B). An extensive 
induction of apoptosis was noted in tumors treated 
by sequential CDDP/Adv-p53 therapy as compared 
with those treated with Adv-p53 only or controls 
(Fig. 3). The magnitude of tumor growth suppres- 
sion achieved by the other treatment regimens 
(CDDP given during or after Adv-p53 injections) 
was more than a simple addition of tumoricidal 
effects attributable to either CDDP or Adv-p53 
alone. In these cases, transduction ofwildtype p53 to 
the p53-negative cells may have made these cells 
more susceptible to CDDP, an observation reported 
by Fujiwara and associates. 6 The gene therapy strat- 
egy presented in this report, which involves a 
CDDP-induced enhancement of p53 gene expres- 
sion and elevated p53-mediated cell arrest or apo- 
ptosis, shows the highest degree of tumor growth 
inhibition. 
We have developed a new, more effective gene 
therapy strategy using the sequential combination of 
CDDP administration a d adenovirus-mediated p53
gene transfer for the treatment of NSCLC. This is a 
particularly attractive and clinically applicable can- 
cer gene therapy strategy for several reasons: (1) 
p53 mutations are quite prevalent in many types of 
cancer; (2) CDDP-induced enhancement of gene 
expression has been observed in other malignant 
cells of different issue origins, 5 and (3) CDDP is a 
commonly used chemotherapeutic agent. This gene 
therapy strategy is now being tested for lung cancer 
in a phase I clinical trial at our institution. 
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Fig. 3. Extensive induction of apoptosis in H1299 tumors treated with the combination of sequential 
intraperitoneal CDDP and intratumoral Adv-p53 injections as analyzed by the in situ TUNEL assay. 
Treatments: A, positive control; B, normal; C, intraperitoneal CDDP; D, PBS/d1312; E, CDDP/d1312; F, 
PBS/Adv-p53; G, CDDP/Adv-p53. Nuclei of apoptotic ells containing fragmented DNA are stained 
brown. 
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Discussion 
Dr. Larry R. Kaiser (Philadelphia, Pa.). Were you 
injecting your adenoviral construct into visible tumor 
nodules? How long had your tumor nodules been growing 
subcutaneously in the nude animals before you injected 
them? 
Dr. Nguyen. It took about 3 weeks to achieve avolume 
of 250 mm 3. 
Dr. Kaiser. And you were using irradiated nude mice as 
well. Does this tumor not grow in nude mice that have not 
been irradiated? 
Dr. Nguyen. It would take about 5 weeks to grow in 
unirradiated nude mice. 
Dr. Kaiser. Did you look at transgene persistence as 
well? You did some reinjection studies, I guess the 
thought being that you may have looked at transgene 
persistence. It was not particularly ong, so you reinjected, 
which gets into some additional questions that we can talk 
about as well. 
Dr. Nguyen. When we study p53 immunohistochemical 
staining or apoptosis beyond 24 or 48 hours, usually the 
cells have already gone to apoptosis and we could not 
detect it. However, when we use a reporter gene like 
/3-galactosidase, we could detect expression of the gene up 
to 10 days or even longer. 
Dr. Kaiser. You did your reinjection how many days 
after the first injection? 
Dr. Nguyen. This was 10 days after the last injection; 
that means 10 days after completion of the gene therapy 
protocol. 
Dr. Kaiser. Did you look then at persistence after the 
second injection as well, because even in these nude 
animals, there is still some cellular immune response? 
Was your transgene persistence attenuated with the sec- 
ond injection? 
Dr. Nguyen, No, we did not look at that. We haven't 
made a detailed analysis of the growth curve after the 
second cycles, but to us it appeared that the second cycle 
is not as strong as the first cycle. It might be related to the 
tumor size at the second cycle of injections. As you know, 
once the tumor develops and the number of cells increase, 
we would use the same number of viral particles, and the 
MOI would decrease. 
Dr. Kaiser. It seems that you are suppressing growth 
over a period of time, but is it just a time-related 
phenomenon? It does seem that even after the second 
injection, you still are seeing some increase in growth in 
the nodule. Have you looked at any other ways of 
combining therapy to try to attenuate that? 
Dr. Nguyen. Yes. 
Dr. Kaiser. You have used a cell line that has a deleted 
p53. Have you evaluated any lines that have a mutated p53 
to see if you get the same results putting in the wildtype 
p53 construct? 
Dr. Nguyen. To answer your second question first: In 
terms of the status of p53, we used a deleted p53 cell line. 
However, all the studies in our laboratory and others have 
demonstrated that the effects should be the same with a 
mutated p53. We use this to give us an advantage so that 
we can detect he wildtype p53 expression more easily. 
Otherwise we have to use a marker, for example, flag p53, 
to detect p53 expression i cells that express mutated p53. 
To answer that question, we have not done the experi- 
ment, but in vitro data indicated that it should give the 
same effects whether we have mutated or deleted p53. 
To answer the first question, our goal is to try to 
eradicate a tumor. We can use a combination of CDDP 
followed by Adv-p53 gene transfer followed by CDDP or 
irradiation, because there are existing experimental data 
to indicate that restoration of wildtype p53 status can 
sensitize malignant cells having deleted or mutated p53 
gene to subsequent external beam irradiation or systemic 
chemotherapy. 
Dr. Kaiser. Have you looked at this in a syngeneic 
model that is immunocompetent? The biggest question 
with adenoviral gene therapy is the immune response. 
Adenovirus stimulates quite an effective immune re- 
sponse, certainly from the first injection, and then the 
question arises about rechallenging these animals that 
now are no longer naive. 
Dr. Nguyen. No, we have not evaluated this in a 
syngeneic model. The vector is always a thorny issue for 
gene therapists, and work is being done in that field. I do 
think that in an immunocompetent host the tumor sup- 
pression effect is probably better. Recent work indicates 
that a tumor-suppression effect can be induced with 
/3-galactosidase alone because of the inducing of anti-/3- 
galactosidase T cells. 
Dr. Kaiser. That probably is not the case. In fact, the 
immune system seems to work very definitely against this, 
as we have shown. The persistence of the transgene is so 
short, especially when rechallenged, that it seems to be 
much more of a problem than any of us had anticipated. 
My other question concerns the bystander effect. Ini- 
tially your group talked about a bystander effect with p53 
and then we never heard anything else about it. Have you 
done any more work with the bystander effect? 
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Dr. Nguyen. Yes, we are still working on that, but it is 
not as prominent as we thought it could be. It has been 
well demonstrated in mixed experiments hat there was a 
bystander effect when the retroviral vector was used with 
p53, and we have seen some results, but the effect is not as 
concrete as with the HSV-TK system that you have been 
working with. 
Dr. Jhingook Kim (Seoul, Korea). I have some ques- 
tions that may be similar to Dr. Kaiser's questions. First, 
how do you decide the amount of the CDDP in your 
experiment? Just with CDDP, we sometimes see apoptosis 
and growth suppression i  the cultured lung cancer cell 
lines. What is your experimental base to choose that dose 
of the CDDP? 
My second question concerns the mechanism of the 
improved effectiveness. Do you think the improvement of
your gene therapy is due to the increased infection rate or 
increased cytocidal effects of the delivered p53? 
My third question is similar to Dr. Kaiser's question. 
Why do you apply your second dose of gene therapy at 
that time? Are you afraid of the immunity of the adeno- 
virus if you use it after growth of the tumor? 
Dr. Nguyen. To answer your question about the dose 
and the schedules, that stemmed from our previous tudy 
using the/3-galactosidase gene as the reporter gene, and 
we did dose-response tudies as well as time studies. We 
demonstrated maximum enhancement only at this dose. 
This is not a tumor-killing dose. At this dose there is no 
change in cell growth characteristic. We did the studies in 
vivo as well, and there is no evidence of apoptosis at this 
dose. This dose somehow stimulated cells to express the 
gene better. It is not a phenomenon of increased uptake of 
viral particles. We did studies as well, and we demon- 
strated that there is an increased expression of the suc- 
cessfully transfused viral particles. 
The dose was derived from studies that we did with the 
/3-galactosidase g ne. Similarly, for in vivo studies we 
demonstrated an enhanced expression of the/3-galactosi- 
dase gene 2 and 4 days after infection when we used a 
dose of 5 txg/gm of body weight. That is why we used this 
dose and that is why we used these time schedules. 
It is not clear why CDDP, which damages deoxyribo- 
nucleic acid (DNA), produces this kind of enhancement 
effect. We have seen that with other drugs as well that 
have a DNA-damaging effect, such as VP-16, and we have 
seen that with irradiation as well. It must have something 
to do with damage to DNA, DNA repair, and probably it 
creates a microenvironment that is favorable for DNA 
expression. There is thus an increase in expression of the 
gene rather than an increased uptake of viral particles. 
I agree with you about immune reactions. That is going 
to be a big issue for gene therapists. We just want to see 
whether having a second-cycle therapy in our model can 
suppress tumor growth further. If it is going to be a 
problem in the syngeneic model, then our impetus would 
be to kill the tumor in the first attempt. That is the whole 
idea of our experiment, which is to enhance the tumor- 
killing effect. 
